Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2022 Earnings Conference Call March 30, 2023 8:00 AM ET

Company Participants

Michael Wood - LifeSci Advisors

Chaim Lebovits - President and Chief Executive Officer

Stacy Lindborg - Co-Chief Executive Officer

Alla Patlis - Interim Chief Financial Officer

David Setboun - Chief Operating Officer

Conference Call Participants

Jason McCarthy - Maxim Group

David Bautz - Zacks Small-Cap Research

Operator

Greetings, and welcome to the Brainstorm Cell Therapeutics Fourth Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. As a reminder, this call is being recorded.

And I will now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood

Good morning and thank you for joining us. Earlier today, Brainstorm issued a press release with its financial results for the full-year 2022, including a corporate update. Before passing it off to the company management for prepared remarks, I'd like to remind listeners that this conference call and webcast will contain numerous statements, descriptions, forecasts and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative orders, such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2023 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time-to-time in the company's SEC filings. The company's results may differ materially from those projected on today's conference call and the company undertakes no obligation to publicly update any forward-looking statements.

Joining us on the call today will be Mr. Chaim Lebovits President and CEO of Brainstorm; Dr. Stacy Lindborg, Co-Chief Executive Officer and Alla Patlis, Interim Chief Financial Officer. In addition, Dr. David Setboun, Executive VP and Chief Operating Officer are also on the call and will be available to answer your questions during the Q&A session.

I’d now like to turn the call over to Mr. Lebovits. Please go ahead.

Chaim Lebovits

Good morning. Thank you, Michael. I want to thank all of you that joined us to discuss our 2022 financial results and recent developments. Throughout 2022, Brainstorm had a number of important clinical and operational achievements, which we believe position the company for further success in the year ahead. Our priority in 2023 is to advance NurOwn through the regulatory process as expeditiously as possible. On this front, we were very excited to announce earlier this week that the FDA intends to hold an advisory committee meeting to discuss our BLA seeking NurOwn’s approval as a treatment for ALS.